Two-year ocular and developmental outcomes of a phase 1 dosing study of bevacizumab for retinopathy of prematurity

David K. Wallace,Amra Hercinovic,Sharon F. Freedman,Eric R. Crouch,Amit R. Bhatt,M. Elizabeth Hartnett,Michael B. Yang,David L. Rogers,Amy K. Hutchinson,William V. Good,Michael X. Repka,Raymond T. Kraker,Susan A. Cotter,Jonathan M. Holmes

Journal of American Association for Pediatric Ophthalmology and Strabismus（2022）

引用 0|浏览14

暂无评分

摘要

Previously, we reported intravitreous bevacizumab doses as low as 0.004 mg (<1% of BEAT-ROP dose) were effective in treating type 1 ROP. We now report two-year outcomes after low-dose and very low-dose bevacizumab.

查看译文

关键词

retinopathy,bevacizumab,prematurity,two-year

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要